A Rarity, Oncocytoma of the Eyelid

Öz 57 Perçin Karakol1, Tevfik Balıkçı1, Cem Leblebici2 1Health Science University Turkey, Bağcılar Training and Research Hospital, Clinic of Plastic, Reconstructive and Aesthetic Surgery, İstanbul, Turkey 2İstanbul Training and Research Hospital, Clinic of Pathology, İstanbul, Turkey CASE REPORT Address for Correspondence: Perçin Karakol, Health Science University Turkey, Bağcılar Training and Research Hospital, Clinic of Plastic, Reconstructive and Aesthetic Surgery, İstanbul, Turkey E-mail: ppercin@gmail.com ORCID ID: orcid.org/0000-0003-0068-2139 Received: 07.01.2020 Accepted: 03.04.2020 Cite this article as: Karakol P, Balıkçı T, Leblebici C. A Rarity, Oncocytoma of the Eyelid. Bagcilar Med Bull 2020;5(2):57-59 ©Copyright 2020 by the Health Sciences University Turkey, Bagcilar Training and Research Hospital Bagcilar Medical Bulletin published by Galenos Publishing House. Introduction Oxyphilic adenomas (oncocytomas) are generally benign, rarely malignant tumors with distant spread. Hamper described it benign adenomatous tumours composed of oncocytes (1). Metastasis often depends on the exact site. These tumors could have been found in several organs including kidneys, liver, breasts, testes, endocrinal glands such as adrenals, thyroid-parathyroid and pituitary glands. Oculer forms are not common and usually examined in benign form. Some of them have orbital involvement, the incidence of ocular oncocytoma has been estimated to be 0.3 per milion/year (2), often considered as malignant. Eyelid forms are very infrequent and surgical excision is the rightful treatment of choice. However, although very rare, recurrence of the eyelid, lacrimal sac and lacrimal gland have been reported (3,4). Case Report A 66-year-old man presented in 2014 with a three year of slowly enlarging five lesions with the diameter of 0.2 cm min to 0.4 cm maximum at the left lower eyelid (Image 1). According to the patient, there was no discomfort or pain but only cosmetic problem on the first examination. Lesions were found to be brownish to reddish in colour, round shaped and tended to fluctuate. All of them were completely removed and excision material was sent to pathology department. Results The light microscopic examination showed a tumor composed of tubulopapillary structures lined by large cells with eosinophilic granular cytoplasm (Figure 1 and 2). No atypia, mitotic activity, necrosis, or hemorrhage was identified. The histological diagnosis of oncocytoma was Bagcilar Med Bull 2020;5(2):57-59 DO I: 10.4274/BMB.galenos.2020.02.03 Karakol et al. Eyelid Oncocytoma Bagcilar Medical Bulletin, Volume 5, Issue 2, June 2020 established. By the way, the patient was followed up for one year, week by week prior to the surgery for the first month and once every three months, respectively. Radiotherapy was not a choice of treatment after the operation. There was no sign of recurrence, neither metastatic lesions through this period. Therefore, a complete surgical excision and a closure with advencement flep made from lower lid skin was performed. We complied with all the reconstructional principles of eyelid closure. A comfortable and cosmeticaly satisfactory result was gained with no complaints from the patient who continued being asymptomatic. Discussion Brick and Schiagenhauffwere mentioned the oncocytes in the ophthalmic regions by noting their presence in the lacrimal glands (5). First case of an oncocytoma of the ocular adnexae was reported by Radnot (6). In the literature, there are limited cases of the upper of lower eyelid with onocytomas. The reason behind this is the rarity of the oncocytomas of ocular appendages. These tumors may develop in the lacrimal glands (7), sac (7-10), and the caruncle (7-9,11-15). Some palpebral oncocytomas like this case originate from the epithelium of Moll’s gland or from the epithelium of the lacrimal duct (1619). In spite of appereance of oncocytes in the lacrimal apparatus, palpebral involvement is a rare site for tumor formation (20). These tumors ordinarily grow slowly and stay asymptomatic. On the other hand, local recurrence can sometimes be seen in malign formations, notably after partial excisions. It was reported by Perlman et al. (21) and Tomic et al. (22) that recurrance could be likely after surgery. So, complete excision, close observation, and routine follow-up are advised. In our case, because the tumors were in a plural-flat form, it was complicated to be sure for deciding whether they were originated from lid or somewhere else. Oncocytomas manifesting themselves in the ocular adnexa region are rare. Regardless of their benign features, developing into a malignant pattern is always possible. In the current case, we addressed oncocytomas might have gone unnoticed, often been referred as a different skin lesion because of their nevus-like appearance to the naked eye. We need to study and examine these tumors 58 Image 1. Patient’s lower eyelid Figure 1. Multiple tubulopapillary proliferations lined by epithelial cells with intensely eosinophilic cytoplasm (HE, x100) Figure 2. Columnar cells with granular, eosinophilic cytoplasm, indicating an oncocytic lesion (HE, x400) Karakol et al. Eyelid Oncocytoma Bagcilar Medical Bulletin, Volume 5, Issue 2, June 2020 more precisely for a proper diagnosis, determination, and rightful treatment. This can lead us to find the tumors’ exact origin, foresee malignant progression and also describe the clinical-histological factors truely. By reporting a patient having oncocytomas on his lower eyelid, we aimed to emphazise this issue particularly. Ethics Informed Consent: All forms of consent are available to share the patient’s photos and data after surgery. Peer-review: Externally peer-reviewed. Authorship Contributions Concept: P.K., C.L., Design: P.K., C.L., Data Collection or Processing: P.K., T.B., Analysis or Interpretation: P.K., T.B., Writing: P.K. Conflict of Interest: The authors declare that there is no conflict of interest with regard to this manuscript. Financial Disclosure: No financial support was received from a person or a company for writing this case report.